67228

Treatment of extensive or progressive retinopathy (eg, diabetic retinopathy), photocoagulation

Current Procedural Terminology (CPT) code 67228 represents the surgical treatment of extensive or progressive retinopathy, most commonly utilized for the management of diabetic retinopathy, utilizing photocoagulation. This procedure is clinically recognized as panretinal photocoagulation (PRP) or scatter laser photocoagulation. The fundamental goal of this ophthalmic surgical intervention is to arrest the progression of neovascularization, which is the abnormal growth of fragile new blood vessels in the retina or iris driven by severe retinal ischemia. Conditions such as proliferative diabetic retinopathy (PDR), severe non-proliferative diabetic retinopathy (NPDR), and ischemic central or branch retinal vein occlusions (CRVO/BRVO) frequently precipitate a state of significant retinal hypoxia. In response to this oxygen deprivation, the ischemic retinal tissue upregulates the secretion of potent angiogenic factors, predominantly Vascular Endothelial Growth Factor (VEGF). This biochemical cascade leads to neovascularization, posing severe threats to vision through complications like vitreous hemorrhage, tractional retinal detachment, and neovascular glaucoma. During the photocoagulation procedure, the operating ophthalmologist utilizes a precisely calibrated medical laser, typically an argon or diode laser, to deliver hundreds to thousands of therapeutic thermal burns to the peripheral and mid-peripheral retina. By intentionally destroying these ischemic peripheral retinal cells, the procedure dramatically reduces the overall metabolic oxygen demand of the retina and subsequently curtails the pathological production of VEGF. This targeted tissue ablation induces regression of the existing fragile neovascular fronds and significantly reduces the risk of future abnormal vessel proliferation. The central macula, responsible for detailed central vision, is meticulously spared during this process to preserve the patient's visual acuity. The surgical intervention requires comprehensive preoperative evaluation, including dilated fundus examination, optical coherence tomography (OCT), and often fluorescein angiography to map the areas of ischemia. The procedure is typically performed in an outpatient setting using topical anesthesia, sometimes supplemented with a peribulbar or retrobulbar block for patient comfort, especially if extensive laser application is anticipated. A specialized ocular contact lens is applied to the cornea to neutralize its refractive power, stabilize the eye, and provide the surgeon with a magnified, stereoscopic, and highly illuminated view of the retinal periphery. The surgeon then methodically applies the laser spots in a scatter pattern. Depending on the extent of the retinopathy, the treatment may necessitate several hundred to over a thousand laser spots, which may be delivered in a single session or divided across multiple staged sessions to minimize patient discomfort and the risk of post-procedural complications such as macular edema, visual field constriction, or choroidal effusion. Post-operatively, the patient is monitored for intraocular pressure spikes and retinal inflammatory responses, with follow-up appointments scheduled to assess the regression of neovascularization and determine if additional laser supplementation is clinically indicated.

Clinical Indications

  • Proliferative diabetic retinopathy (PDR) with high-risk characteristics
  • Severe non-proliferative diabetic retinopathy (NPDR)
  • Ischemic central retinal vein occlusion (CRVO) with rubeosis iridis or retinal neovascularization
  • Ischemic branch retinal vein occlusion (BRVO) complicated by neovascularization
  • Ocular ischemic syndrome leading to neovascularization
  • Sickle cell retinopathy with neovascular sea fan formations
  • Radiation retinopathy with secondary proliferative changes

Procedure Steps

  1. Verify patient identity, review the targeted eye, confirm diagnosis, and obtain informed surgical consent.
  2. Administer topical anesthetic drops (e.g., proparacaine or tetracaine) and cycloplegic/mydriatic drops (e.g., tropicamide, phenylephrine) to achieve maximum pupillary dilation.
  3. Position the patient comfortably at the slit lamp delivery system or in a supine position if using a laser indirect ophthalmoscope.
  4. Apply a viscous coupling agent (e.g., methylcellulose) to a specialized laser contact lens (e.g., Mainster or panfundus lens) and carefully place it onto the patient's cornea to stabilize the globe and visualize the peripheral retina.
  5. Calibrate the photocoagulation laser (e.g., Argon, Diode, or Nd:YAG) to the appropriate power (mW), exposure duration (ms), and spot size (microns) based on the targeted retinal pigmentation and desired thermal burn intensity.
  6. Systematically apply hundreds to thousands of thermal laser burns in a scatter pattern across the mid-peripheral and peripheral retina, meticulously avoiding the central macula, optic nerve head, and major retinal vasculature.
  7. Carefully remove the contact lens and irrigate the eye with sterile saline to clear the viscous coupling agent.
  8. Monitor the patient briefly for immediate complications, administer post-operative topical anti-inflammatory or intraocular pressure-lowering medications if clinically indicated, and provide detailed discharge instructions and follow-up care schedules.

Coding Guidelines

  • CPT code 67228 should be reported per eye treated. If the procedure is performed bilaterally during the same operative session, append modifier 50 to the code, or use modifiers RT and LT according to specific payer guidelines.
  • This code historically had a 90-day global period but currently has a 10-day global period under Medicare rules. Always verify the specific global period with commercial payers.
  • If the panretinal photocoagulation treatment requires multiple staged sessions to complete the medically necessary treatment plan within the global period, subsequent sessions should be reported with modifier 58 (Staged or related procedure or service by the same physician during the postoperative period).
  • Do not report 67228 in conjunction with code 92018 or 92019 (ophthalmological examination under anesthesia) unless the exam is performed for a distinct, separately identifiable reason (append modifier 59 or X-modifier as appropriate).
  • Topical anesthesia and local nerve blocks (such as retrobulbar blocks) administered by the performing surgeon are included in the intraoperative service and should not be separately reported.
  • Diagnosis coding must accurately reflect the laterality and severity of the retinopathy to support medical necessity.

Associated ICD-10 Codes